Inhibrx and Regeneron, began a research collaboration in 2016. Since that time, the collaboration has focused on researching, developing,and commercializing chimeric antigen receptor (CAR) T-cell therapies using Inhibrx’s proprietary single-domain antibody (sdAb) platform to multiple cancer targets.

• In 2018, Inhibrx granted Regeneron worldwide rights to develop, manufacture, and commercialize certain cell therapy products.
• In 2020, Inhibrx granted Regeneron exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets for two programs and up to an additional eight programs.

Regeneron was formally known as 2seventy bio and bluebird bio.

In June 2012, Inhibrx and Celgene, now a Bristol-Myers Squibb Company, entered into a Development and Option agreement related to our CD47 checkpoint inhibitor.

In July 2013, Celgene opted to exercise its option and was granted an exclusive global license for the development, manufacture, and commercialization of our proprietary CD47 binding domain.

In 2018, Inhibrx and Elpiscience entered into an exclusive license agreement with respect to INBRX-106. Elpiscience has rights to manufacture, develop, and commercialize INBRX-106 in Greater China, while Inhibrx maintains the U.S. and other global rights.